LEMTRADA (alemtuzumab)
ANTINEOPLASTIC MONOCLONAL ANTIBODIES · RELAPSING FORM OF MULTIPLE SCLEROSIS ·+1
GENZYME
Drug class
Multiple Sclerosis Agent - CD52 Specific Monoclonal Antibody
The phrase "Multiple Sclerosis Agent - CD52 Specific Monoclonal Antibody" refers to an established pharmacological classification represented by alemtuzumab, a targeted disease-modifying therapy. Read more about Multiple Sclerosis Agent - CD52 Specific Monoclonal Antibody
1 drugs in this class 1 manufacturers
Drugs in Multiple Sclerosis Agent - CD52 Specific Monoclonal Antibody
Filter & compare in the drug finder →
Opens the drug finder with Multiple Sclerosis Agent - CD52 Specific Monoclonal Antibody preselected. Add indication or manufacturer filters there.
The phrase "Multiple Sclerosis Agent - CD52 Specific Monoclonal Antibody" refers to an established pharmacological classification represented by alemtuzumab, a targeted disease-modifying therapy.
Therapies in this category function by binding specifically to the CD52 antigen expressed primarily on mature circulating B and T lymphocytes, prompting rapid cytolytic depletion through complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity followed by slow, altered immune reconstitution.
These agents are indicated for adults with relapsing forms of multiple sclerosis, including relapsing-remitting disease and active secondary progressive disease.
Because of significant safety considerations, such as secondary autoimmune disorders and infusion reactions, their clinical role is generally reserved for patients with highly active disease or an inadequate response to alternative therapies.
-
fda.gov
The phrase "Multiple Sclerosis Agent - CD52 Specific Monoclonal Antibody" refers to an established pharmacological classification represented by alemtuzumab, a targeted disease-modifying therapy These agents are indicated for adults with relapsing forms of multiple sclerosis, including relapsing-remitting disease and active secondary progressive disease Because of significant safety considerations, such as secondary autoimmune disorders and infusion reactions, their clinical role is generally re...
-
drugs.com
The phrase "Multiple Sclerosis Agent - CD52 Specific Monoclonal Antibody" refers to an established pharmacological classification represented by alemtuzumab, a targeted disease-modifying therapy Therapies in this category function by binding specifically to the CD52 antigen expressed primarily on mature circulating B and T lymphocytes, prompting rapid cytolytic depletion through complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity followed by slow, altered immune recons...
-
fda.gov
Therapies in this category function by binding specifically to the CD52 antigen expressed primarily on mature circulating B and T lymphocytes, prompting rapid cytolytic depletion through complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity followed by slow, altered immune reconstitution Because of significant safety considerations, such as secondary autoimmune disorders and infusion reactions, their clinical role is generally reserved for patients with highly active dis...
-
pharmacytimes.com
Therapies in this category function by binding specifically to the CD52 antigen expressed primarily on mature circulating B and T lymphocytes, prompting rapid cytolytic depletion through complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity followed by slow, altered immune reconstitution
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.